Philippe Bouchard
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Philippe Bouchard has a total of 25 co-authors. Here are the top co-authors by number of shared publications:
E. Gainer
3 shared publicationsN. Chabbert-Buffet
3 shared publicationsM. Roger
2 shared publications- Najiba Lahlou
Hormonal Biology Laboratory, St Vincent de Paul Hospital, Paris, France
2 shared publications A. Pintiaux-Kairis
Département de Gynécologie Obstétrique, CHU de Liège, Belgique
1 shared publicationB M Mannaerts
Department of Obstetrics and Gynecology, Dijkzigt University Hospital, Rotterdam, The Netherlands
1 shared publication
Latest Publications
- 1 May 2010
- Published by Elsevier in Annales d'Endocrinologie
- Vol. 71 (3) , 225-227
Treatment of infertility in women with polycystic ovary syndrome
- 1 May 2010
- Published by Elsevier in Annales d'Endocrinologie
- Vol. 71 (3) , 225-227
Treatment of infertility in women with polycystic ovary syndrome
- 1 October 2006
- Published by Elsevier in Annales d'Endocrinologie
- Vol. 67 (5) , 392
CO25 - L’hormone anti-mullerienne (AMH) est secrétée selon un modèle diphasique dans les cycles ovulatoires
- 1 October 2006
- Published by Elsevier in Annales d'Endocrinologie
- Vol. 67 (5) , 392
CO25 - L’hormone anti-mullerienne (AMH) est secrétée selon un modèle diphasique dans les cycles ovulatoires
- 30 September 2006
- Published by Elsevier in Fertility and Sterility
- Vol. 86 (3) , S11-11
O-24: Diphasic pattern of anti-mullerian hormone (AMH) in ovulatory cycles as evidenced by means of an ultra-sensitive assay: New insights into ovarian function
- 30 September 2006
- Published by Elsevier in Fertility and Sterility
- Vol. 86 (3) , S11-11
O-24: Diphasic pattern of anti-mullerian hormone (AMH) in ovulatory cycles as evidenced by means of an ultra-sensitive assay: New insights into ovarian function
- 1 January 2005
- Published by Taylor & Francis in Gynecological Endocrinology
- Vol. 21 (3) , 142-148
Bleeding profile and endometrial safety of continuous combined regimens 1 mg 17 beta -estradiol/trimegestone versus 1 or 2 mg 17 beta -estradiol/norethisterone acetate in postmenopausal women
Objective. To compare the bleeding profile and endometrial safety of continuous combined 1 mg 17β-estradiol (17β-E2) and 0.125 mg trimegestone (TMG) with those of two continuous combined 17β-E2 and norethisterone acetate (NETA) regimens. Study design. This was a double-blind, randomized, multicenter study conducted in 12 European countries and Israel over a 2-year period. Healthy postmenopausal women with an intact uterus were given either 1 mg 17β-E2/0.125 mg TMG, 2 mg 17β-E2/1 mg NETA or 1 mg 17β-E2/0.5 mg NETA for up to 26 cycles, each of 28 days. Results. The percentage of amenorrheic women was greater in most cycles up to cycle 13 in the 1 mg 17β-E2/0.125 mg TMG group than in the comparator groups. The mean number of bleeding days was similar in the 1 mg 17β-E2/0.125 mg TMG and the 1 mg 17β-E2/0.5 mg NETA groups, but greater in the 2 mg 17β-E2/1 mg NETA group. No endometrial hyperplasia was observed for any group. Conclusion. Continuous combined 1 mg 17β-E2/0.125 mg TMG exhibits a more favorable bleeding profile than 1 mg 17β-E2/0.5 mg NETA up to 1 year, while providing an adequate protective effect on the endometrium.
- 1 January 2005
- Published by Taylor & Francis in Gynecological Endocrinology
- Vol. 21 (3) , 142-148
Bleeding profile and endometrial safety of continuous combined regimens 1 mg 17 beta -estradiol/trimegestone versus 1 or 2 mg 17 beta -estradiol/norethisterone acetate in postmenopausal women
Objective. To compare the bleeding profile and endometrial safety of continuous combined 1 mg 17β-estradiol (17β-E2) and 0.125 mg trimegestone (TMG) with those of two continuous combined 17β-E2 and norethisterone acetate (NETA) regimens. Study design. This was a double-blind, randomized, multicenter study conducted in 12 European countries and Israel over a 2-year period. Healthy postmenopausal women with an intact uterus were given either 1 mg 17β-E2/0.125 mg TMG, 2 mg 17β-E2/1 mg NETA or 1 mg 17β-E2/0.5 mg NETA for up to 26 cycles, each of 28 days. Results. The percentage of amenorrheic women was greater in most cycles up to cycle 13 in the 1 mg 17β-E2/0.125 mg TMG group than in the comparator groups. The mean number of bleeding days was similar in the 1 mg 17β-E2/0.125 mg TMG and the 1 mg 17β-E2/0.5 mg NETA groups, but greater in the 2 mg 17β-E2/1 mg NETA group. No endometrial hyperplasia was observed for any group. Conclusion. Continuous combined 1 mg 17β-E2/0.125 mg TMG exhibits a more favorable bleeding profile than 1 mg 17β-E2/0.5 mg NETA up to 1 year, while providing an adequate protective effect on the endometrium.
- 1 September 2002
- Published by Springer Nature in Reviews in Endocrine and Metabolic Disorders
- Vol. 3 (3) , 173-183
The Normal Human Menstrual Cycle
- 1 September 2002
- Published by Springer Nature in Reviews in Endocrine and Metabolic Disorders
- Vol. 3 (3) , 173-183
The Normal Human Menstrual Cycle
- 1 January 2000
- Published by Elsevier in Fertility and Sterility
- Vol. 73 (1) , 18-20
Gonadotropin-releasing hormone antagonist: new tools vs. old habits
- 1 January 2000
- Published by Elsevier in Fertility and Sterility
- Vol. 73 (1) , 18-20
Gonadotropin-releasing hormone antagonist: new tools vs. old habits
- 15 June 1999
- Vol. 49 (12) , 1270-6
[Physiology and exploration of the gonadotropic axis].
The physiology of the hypothalamus-pituitary-gonadal axis includes endocrine interactions between the hypothalamopituitary system and the gonads, as well as paracrine interactions within the various endocrine glands of the reproductive system (pituitary, ovary, testis). The pulsatile secretion of GnRH by the hypothalamus stimulates the pulsatile secretion of gonadotropins (LH and FSH) by the pituitary. LH and FSH regulate the hormonal production of the gonads as well as gametogenesis. The steroid (oestradiol, progesterone, testosterone) and peptide (inhibins) hormones produced by the gonads regulate in turn hypothalamopituitary secretions. The exploration of the hypothalamo-pituitary-gonadal axis relies mainly on the analysis of few, carefully scheduled, basal state hormonal evaluations. A confrontation of these hormonal assessments with physical examination is crucial.
- 15 June 1999
- Vol. 49 (12) , 1270-6
[Physiology and exploration of the gonadotropic axis].
The physiology of the hypothalamus-pituitary-gonadal axis includes endocrine interactions between the hypothalamopituitary system and the gonads, as well as paracrine interactions within the various endocrine glands of the reproductive system (pituitary, ovary, testis). The pulsatile secretion of GnRH by the hypothalamus stimulates the pulsatile secretion of gonadotropins (LH and FSH) by the pituitary. LH and FSH regulate the hormonal production of the gonads as well as gametogenesis. The steroid (oestradiol, progesterone, testosterone) and peptide (inhibins) hormones produced by the gonads regulate in turn hypothalamopituitary secretions. The exploration of the hypothalamo-pituitary-gonadal axis relies mainly on the analysis of few, carefully scheduled, basal state hormonal evaluations. A confrontation of these hormonal assessments with physical examination is crucial.
- 1 June 1992
- Published by The Endocrine Society in The Journal of Clinical Endocrinology & Metabolism
- Vol. 74 (6) , 1471-1473
Human recombinant follicle-stimulating hormone induces growth of preovulatory follicles without concomitant increase in androgen and estrogen biosynthesis in a woman with isolated gonadotropin deficiency.
To evaluate the importance of luteinizing hormone (LH) for normal estrogen production and subsequent development of ovarian follicles, a woman with isolated gonadotropin deficiency (LH; 0.37 IU/L, FSH 1.2 IU/L) was monitored during recombinant human follicle-stimulating hormone (hFSHrec) administration with respect to ovarian follicular growth and steroid production. During the first week (75 IU/day hFSHrec im) a significant rise in serum FSH (4.9 IU/L) was observed in the absence of changes in serum estradiol (E2) concentrations (36-76 pmol/L). During the following five days 150 IU/day hFSHrec was administered resulting in a further increase of serum FSH levels (maximum 8.5 IU/L). Development of multiple follicles--maximum diameter 22 mm as observed by transvaginal sonography--emerged together with a minor rise in E2 levels (from 76 to 236 pmol/L) and with a minimal increase in endometrial thickness (below 6 mm). Six days following the last injection of hFSHrec, aspiration of 3 follicles (13, 15 and 18 mm) was performed and low intrafollicular androstenedione (AD) (less than 675 nmol/L) and E2 (less than 9400 pmol/L) concentrations as compared to normal follicles were found. These first data on hFSHrec administration in the human suggest that; a) FSH alone can induce growth of preovulatory follicles, b) follicle growth does occur in the presence of subnormal E2 levels, c) LH is needed for adequate AD biosynthesis as substrate for aromatase activity. This indicates that growth and steroidogenic granulosa cell activity may be differentially regulated.
- 1 June 1992
- Published by The Endocrine Society in The Journal of Clinical Endocrinology & Metabolism
- Vol. 74 (6) , 1471-1473
Human recombinant follicle-stimulating hormone induces growth of preovulatory follicles without concomitant increase in androgen and estrogen biosynthesis in a woman with isolated gonadotropin deficiency.
To evaluate the importance of luteinizing hormone (LH) for normal estrogen production and subsequent development of ovarian follicles, a woman with isolated gonadotropin deficiency (LH; 0.37 IU/L, FSH 1.2 IU/L) was monitored during recombinant human follicle-stimulating hormone (hFSHrec) administration with respect to ovarian follicular growth and steroid production. During the first week (75 IU/day hFSHrec im) a significant rise in serum FSH (4.9 IU/L) was observed in the absence of changes in serum estradiol (E2) concentrations (36-76 pmol/L). During the following five days 150 IU/day hFSHrec was administered resulting in a further increase of serum FSH levels (maximum 8.5 IU/L). Development of multiple follicles--maximum diameter 22 mm as observed by transvaginal sonography--emerged together with a minor rise in E2 levels (from 76 to 236 pmol/L) and with a minimal increase in endometrial thickness (below 6 mm). Six days following the last injection of hFSHrec, aspiration of 3 follicles (13, 15 and 18 mm) was performed and low intrafollicular androstenedione (AD) (less than 675 nmol/L) and E2 (less than 9400 pmol/L) concentrations as compared to normal follicles were found. These first data on hFSHrec administration in the human suggest that; a) FSH alone can induce growth of preovulatory follicles, b) follicle growth does occur in the presence of subnormal E2 levels, c) LH is needed for adequate AD biosynthesis as substrate for aromatase activity. This indicates that growth and steroidogenic granulosa cell activity may be differentially regulated.